Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $88.50M | $-35.27M | $-4.67 |
| 2024 | $71.32M | $-42.93M | $-6.62 |
| 2023 | $49.09M | $-52.15M | $-12.70 |
| 2022 | $38.21M | $-65.45M | $-31.09 |
| 2021 | $54.51M | $-43.16M | $-31.54 |
Social Signal Score
Earnings
Mon, Nov 2(in 3 months)
Consensus estimate $-0.74 per share
Typical surprise +21.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.71 vs $-0.90beat
- Mon, May 4$-0.81 vs $-1.26beat
- Thu, Feb 26$-0.49 vs $-1.05beat
- Mon, Nov 3$-1.16 vs $-1.60beat
- Thu, Aug 7$-1.60 vs $-1.40miss
- Tue, May 13$-0.08 vs $-0.08beat
Estimates and results for BDSX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
BDSXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsmarketbeat.com·2d ago·Neutral
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
View source ↗ - Newszacks.com·4d ago·Positive
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗